Mallinckrodt Plc (MNK): Mark Trudeau , CEO of Mallinckrodt Plc purchased 1,000 shares on May 6, 2016. The Insider buying transaction was reported by the company on May 9, 2016 to the Securities and Exchange Commission. The shares were purchased at $56.02 per share for a total value of $56,020.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 8, 2016, Coleman N Iii Lannum (Sr.VP, Investor Strategy & IRO) purchased 2,600 shares at $62.63 per share price.On Mar 1, 2016, Meredith B Fischer (Sr. VP, Comm & Public Affairs) purchased 1,400 shares at $69.91 per share price.Also, On Feb 10, 2016, Matthew K Harbaugh (CFO) purchased 1,300 shares at $63.00 per share price.On Dec 18, 2015, Virgil D Thompson (director) sold 18,000 shares at $73.62 per share price.
Shares of Mallinckrodt PLC (MNK) ended Friday, May 6, 2016 session in red amid volatile trading. The shares closed down -4.42 points or -7.27% at $56.4 with 67,98,716 shares getting traded. Post opening the session at $59.02, the shares hit an intraday low of $54.5201 and an intraday high of $59.53 and the price vacillated in this range throughout the day. The company has a market cap of $6,166 M and the number of outstanding shares has been calculated to be 10,93,25,511 shares. The 52-week high of Mallinckrodt PLC is $132.6 and the 52-week low is $50.9.
Company has been under the radar of several Street Analysts.Mallinckrodt PLC is Reiterated by Mizuho to Buy and the brokerage firm has raised the Price Target to $ 80 from a previous price target of $78 .The Rating was issued on May 4, 2016.Mallinckrodt PLC is Initiated by Wells Fargo to Outperform. The Rating was issued on Feb 19, 2016.
Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops manufactures markets and distributes both branded and generic specialty pharmaceuticals active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops manufactures and sells through its Brands business drugs including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide) a neonatal critical care product.